The economic burden of type 2 diabetes on the public healthcare system in Kenya: a cost of illness study

被引:0
|
作者
Karugu, Caroline H. [1 ,2 ]
Agyemang, Charles [2 ]
Ilboudo, Patrick Gueswende [1 ]
Boachie, Micheal Kofi [3 ,4 ]
Mburu, Lilian [1 ]
Wanjohi, Milka [1 ]
Sanya, Richard E. [1 ]
Moolla, Aisha [4 ]
Ojiambo, Veronica [1 ]
Kruger, Petronell [4 ]
Vandevijvere, Stefanie [5 ]
Asiki, Gershim [1 ,6 ]
机构
[1] African Populat Hlth Res Ctr, Chron Dis Management Unit, Nairobi, Kenya
[2] Amsterdam Med Ctr, Dept Publ & Occupat Hlth, Amsterdam, Netherlands
[3] Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Discipline Publ Hlth Med, Durban, South Africa
[4] PRICELESS SA, SAMRC Wits Ctr Hlth Econ & Decis Sci, ZA-2193 Johannesburg, South Africa
[5] Serv Lifestyle & Chron Dis, Sciensano, Brussels, Belgium
[6] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden
关键词
Type; 2; diabetes; Chronic diseases; Non-communicable diseases; Cost-of-illness; Bottom-up costing; Public healthcare system; Diabetes complications; Kenya;
D O I
10.1186/s12913-024-11700-x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BackgroundThe burden of chronic non-communicable diseases (NCDs) is a growing public health concern. The availability of cost-of-illness data, particularly public healthcare costs for NCDs, is limited in Sub-Saharan Africa (SSA), yet such data evidence is needed for policy action.ObjectiveThe objective of this study was to estimate the economic burden of type 2 diabetes (T2D) on Kenya's public healthcare system in 2021 and project costs for 2045.MethodsThis was a cost-of-illness study using the prevalence-based bottom-up costing approach to estimate the economic burden of T2D in the year 2021. We further conducted projections on the estimated costs for the year 2045. The costs were estimated corresponding to the care, treatment, and management of diabetes and some diabetes complications based on the primary data collected from six healthcare facilities in Nairobi and secondary costing data from previous costing studies in low and middle-income countries (LMICs). The data capture and costing analysis were done in Microsoft Excel 16, and sensitivity analysis was conducted on all the parameters to estimate the cost changes.ResultsThe total cost of managing T2D for the healthcare system in Kenya was estimated to be US$ 635 million (KES 74,521 million) in 2021. This was an increase of US$ 2 million (KES 197 million) considering the screening costs of undiagnosed T2D in the country. The major cost driver representing 59% of the overall costs was attributed to T2D complications, with nephropathy having the highest estimated costs of care and management (US$ 332 million (KES 36, 457 million). The total cost for T2D was projected to rise to US$ 1.6 billion (KES 177 billion) in 2045.ConclusionThis study shows that T2D imposes a huge burden on Kenya's healthcare system. There is a need for government and societal action to develop and implement policies that prevent T2D, and appropriately plan care for those diagnosed with T2D.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Cost-of-illness study of type 2 diabetes mellitus in Colombia
    Camilo Gonzalez, Juan
    Walker, John H.
    Einarson, Thomas R.
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2009, 26 (01): : 55 - 63
  • [22] Cost-of-illness study of diabetes mellitus: focus on patients with type 2 diabetes
    Pirolo, Roberta
    Bettiol, Alessandra
    Bolcato, Jenny
    Franchin, Giulia
    Deambrosis, Paola
    Paccagnella, Agostino
    Giusti, Pietro
    Chinellato, Alessandro
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2016, 3 (01) : 32 - 41
  • [23] Incremental healthcare costs attributable to type 2 diabetes in Hong Kong: A population-based cost of illness study
    Quan, Jianchao
    Ng, Carmen S.
    DIABETIC MEDICINE, 2023, 40 (02)
  • [24] Estimating the economic burden of stroke in China: a cost-of-illness study
    Ma, Jingdong
    Tian, Zeshi
    Chai, Peipei
    Wan, Quan
    Zhai, Tiemin
    Guo, Feng
    Li, Yan
    BMJ OPEN, 2024, 14 (03):
  • [25] ECONOMIC BURDEN OF HEART FAILURE IN SAUDI ARABIA: A COST OF ILLNESS STUDY
    Alghamdi, A.
    Alqarni, E.
    Altowaijri, A.
    VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [26] The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study
    Ingrid A. Cox
    Barbara de Graaff
    Hasnat Ahmed
    Julie Campbell
    Petr Otahal
    Tamera J. Corte
    Yuben Moodley
    Nicole Goh
    Peter Hopkins
    Sacha Macansh
    E. Haydn Walters
    Andrew J. Palmer
    The European Journal of Health Economics, 2023, 24 : 1121 - 1139
  • [27] The economic burden of tuberculosis in Cyprus. A probabilistic cost of illness study
    Zannetos, Sawas
    Zachariadou, Theodora
    Adamidi, Tonia
    Georgiou, Andreas
    EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH, 2018, 15 (02):
  • [28] The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study
    Cox, Ingrid A.
    de Graaff, Barbara
    Ahmed, Hasnat
    Campbell, Julie
    Otahal, Petr
    Corte, Tamera J.
    Moodley, Yuben
    Goh, Nicole
    Hopkins, Peter
    Macansh, Sacha
    Walters, E. Haydn
    Palmer, Andrew J.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (07): : 1121 - 1139
  • [29] The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study
    Bommer, Christian
    Heesemann, Esther
    Sagalova, Vera
    Manne-Goehler, Jennifer
    Atun, Rifat
    Barnighausen, Till
    Vollmer, Sebastian
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (06): : 423 - 430
  • [30] Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry
    Wittbrodt, Eric
    Bhalla, Narinder
    Andersson Sundell, Karolina
    Gao, Qi
    Dong, Liyan
    Cavender, Matthew A.
    Hunt, Phillip
    Wong, Nathan D.
    Mellstrom, Carl
    ENDOCRINOLOGY DIABETES & METABOLISM, 2020, 3 (03)